The PM Connective’s mission is to become valued integrators in personalized medicine. Based on ongoing research and collaboration with thought leaders across all healthcare industry stakeholders, we will create and validate an integrative new business model that will deliver profound clinical and financial benefits in personalized healthcare. Once developed, the PM Connective will disseminate this model throughout the community in an effort to stimulate discussion, support the development of improved collaborative structures, and accelerate innovation in personalized medicine.
Personalized medicine (PM) is a rapidly evolving field built largely on the premise that a more targeted approach improves outcome and thus saves costs for the healthcare system at large. The latter claim, however, is a focus of much recent debate. Indeed, better ambulatory or clinical outcome should lead to lower expenses for then unnecessary Dx tests and Rx interventions. Yet, there are costs associated also in developing the MDx markers, in the lack of economic scale that smaller patient populations naturally confer and in a likely more personnel-intensive, individualized care management. These issues are compounded by the fact that current strategies of higher pricing for PM, feasible in the context of rare diseases, will be increasingly opposed by both private and public payers for areas of ‘mass’ PM consumption such as cancer. So, who or which models will pay for PM innovation to make it sustainable, and how much?
An additional barrier to unlocking the potential of PM in tandem with delivering sustainable cost management is the complexity of simultaneously integrating novel diagnostics, targeted treatments and timely education into each treatment pathway. Today, most of the stakeholders involved operate in their individual siloes and the mechanisms for collaboration (particularly at the clinical implementation stage) are absent or insufficient, which leads to a poor integration of stakeholders.
The PM Connective understands personalized medicine as a value-driving paradigm that requires the active collaboration of a variety of stakeholders including pharmaceutical, diagnostic and medical device companies as well as healthcare providers and patient advocates. Currently, however, there is uncertainty around whether value capture at one end will lead to loss in value for another stakeholder and as such, collaborations are still scarce and value capture is not optimized over the entire value chain. Therefore, there is a need in the market for an integrative framework to generate, optimize and capture value through these PM collaborations. To address this challenge, the PM Connective has been founded by a group of industry leaders. It functions as an independent non-profit organization.
The PM CONNECTIVE intends to develop and publish its method for aligning stakeholders and outcomes in the two disease areas in focus. The initial 4 phase business model process has been outlined and is graphically represented in the PM CONNECTIVE Tree below.
At the PM Connective we strive to be integrators in personalized healthcare. Our mission is to create and provide ongoing evidence for a systems integration model that will deliver profound clinical and financial benefit in personalized healthcare. Our members believe that the true potential of personalized medicine cannot be fully realized without the creation of new business models and new ways of collaboration from all stakeholders involved in advancing patient care.
Jeff is Executive Director of the PM Connective, a 501(c)(6) non-profit corporation. He is responsible for strategic, operational, and financial leadership of the integrated team. In this capacity, he directs the development of strategic partnerships and collaborations to drive achievement of the PM Connective’s goals in promoting and influencing the advancement and adoption of personalized medicine. Jeff brings to this role a diverse healthcare industry background. Prior to joining the PM Connective, he was Managing Director of the Sherborn Consulting Group where he advised healthcare and life sciences clients on healthcare strategy, new product development and reimbursement strategy. Earlier in his career, he worked in the office of the President of Aetna, directing strategic, financial and operational planning for the enterprise. He subsequently led strategic initiatives in three of Aetna’s key subsidiaries, including the Provider Contacting area, the Wellness and eHealth Product Group and the Pharmacy subsidiary, where he reported to the Clinical Head of Pharmacy. He was also a member of Aetna’s Innovation Council focused on developing new healthcare products. Jeff has a BS in Engineering from Brown University and an MBA in Corporate Strategy and Finance from the University of Pennsylvania’s Wharton School.
As Chief Executive Officer of Diaceutics Group, Peter brings over twenty-six years of experience in international healthcare, first at GSK and Diagnology and then at Diaceutics. In addition to Peter’s extensive operational experience in the US, he also has substantial experience running operations in all the key healthcare markets of the world, including Germany, Indonesia the UK and Japan. Since founding Diaceutics, Peter has combined the need for a standardized and structured process to effectively commercialize and launch companion diagnostics alongside drug development with a group of companies providing customized commercialization services to the pharmaceutical industry.
Peter has spent two extended periods in applied industrial research, including a year at MIT’s Pharmaceutical Program at the Sloan School of Management in Boston and is considered a thought leader in Personalized Medicine commercialization.
Emmanuelle Benzimra was appointed in 2012 General Delegate of EPEMED, the European PErsonalised MEDicine association, a pioneer organisation based in Luxembourg and a catalyst acting to make personalised medicine and diagnostics a reality for European patients. Before that she collaborated with different non-profit start-ups, supporting them from creation, to business development and general management, more especially, Bench2Cures, a foundation dedicated to support biomedical research in Luxembourg. This is when she realised the socio-economic impact of personalised medicine and how developing a unique treatment for each individual should dominate more than ever the medical approach of today and build tomorrow's. It is to defend this principle that she forged a career change on a personal and professional engagement, and yearned to make the best use of her senior experience in business and relationship management acquired along 14 years in international investment banks.
As Chief Financial Officer of Diaceutics Group, Philip has responsibility for all administrative, financial and risk management operations for Diaceutics and its subsidiary companies. The role incorporates working closely with the management team and Board of Directors to develop and implement strategies across the organisation. In addition, Philip is responsible for maintaining compliance with US, UK and Republic of Ireland financial reporting, taxation and corporate governance standards. In his role at Diaceutics, Philip brings over 10 years of financial and management experience as the Finance Director of a company and a global export market as well as significant experience in product development, planning and product launch. Philip is an acting board member of a UK charity and has over 8 years’ experience at board level in the charitable and not for profit sector. Philip has a LLB honours degree in Law and Accounting from Queens University Belfast, as well as a Diploma in Accounting and a Diploma in International Financial Reporting Standards. Philip is a Fellow member of the Institute of Chartered Accountants in Ireland, an associate member of the Institute of Taxation and a Fellow member of the Institute of Directors.
Tiffany Olson is the President of Nuclear Pharmacy Services, Cardinal Health. She leads a network of sites that manufacture, compound, dispense and deliver over 10 million patient doses annually. Directly prior, she was President of NaviMed, a company focused on personalizing medicine through innovative diagnostics. Ms. Olson worked for Eli Lilly and Company, where she lead the effort to create the strategy for companion and commercialized diagnostics. Ms. Olson worked for Roche Diagnostics for many years where she attained the position of President and CEO of Roche Diagnostics Corporation.
Juliesta Sylvester, Ph.D. is co-founder of Panomica, Inc., a software startup that integrates and interprets multi-omic data for clinical decision support. Dr. Sylvester trained in neuroscience and structural genomics, and received her Ph.D. on protein signaling networks in Biochemistry and Molecular Biology at the University of Chicago. Dr. Sylvester worked at the University of Chicago, MIT, and the Scripps Research Institute on innovation platforms for EMD Millipore, Luminex, and Johnson and Johnson that were based on biomarker quantitation, multiplexing, complex systems analyses, and drug discovery. Dr. Sylvester is the principle architect behind the proteomic post-processing software Annotator, which allows for dynamic functional protein annotation and the identification of statistically significant changes in cell behavior.
Is a professional chemist and business manager with 18 years industry experience plus 22 years as a professional recruiter in the Life Sciences and Technology markets.
Jayne also has additional HR expertise gained from running assessment centres and providing value added HR services such as executive coaching, staff evaluation for internal promotions and attitude surveys.
Jayne is active in supporting a number of key industry events in the EU providing services for promotion of technical conferences.
Jayne has successfully completed many international search assignments in pharmaceuticals, biotechnology, chemicals and materials, petrochemical, nuclear and green energy, medical devices, and diagnostics and contract research/manufacturing sectors, plus high tech equipment for both R&D and manufacturing applications in life technologies, medical, aerospace and electronic communications. The range of her assignments has covered all levels from specialist technical role to board level and functions from Discovery Research through Development, Clinical, Regulatory Affairs, HSE, QA, Manufacturing, Sales and Marketing, BD & Licensing.
Paul is currently the SVP, Director of Market Strategy and Development at Corbett, the lead US hub within TBWA\WorldHealth. As the Director of Market Strategy and Development, Paul oversees Corbett’s clinical trial patient recruitment business unit, the scientific/medical strategy division and leads the agency’s efforts in Personalized Healthcare (in partnership with the Diaceutics group). Prior to joining Corbett, Paul was a bench scientist with an interest and focus in cardiovascular disease.
As Chief Medical Officer, Maria is responsible for the development of clinical and laboratory partnerships in the Diaceutics Group, and supports the definition and implementation of the medical and scientific strategy for the team and for client projects. Maria has over 15 years’ experience in healthcare and the biomedical industry, particularly in molecular diagnostics, translational and precision medicine. Prior to joining Diaceutics and founding Labceutics, Maria was head of translational medicine and scientific development in Zeltia SA., coordinating international labs and hospitals, and has over 10 years’ experience setting up and managing laboratories for molecular diagnostics and precision medicine. After her prolific academic phase in Epigenetics, with a good number of peer reviewed publications and direction of several doctoral theses, she was the founder of her own Molecular Diagnostic Labs in Spain. This track record was crucial to founding and developing Labceutics five years ago. In her role as Chief Medical Officer of Diaceutics Group, Maria ensures that Diaceutics client project delivery is based on a comprehensive and up-to-date understanding of scientific developments and clinical needs, and connects Diaceutics to a large network of clinical stakeholders of the highest reputation. Maria completed her studies at Johns Hopkins in the USA, she holds an MD, a PhD and a Master in Social Services/NGOs Administration. She is an active member of the American Society of Clinical Oncology, of the European Society of Medical Oncology, the American Association of Cancer Research and the Spanish Association of Cancer Research.
Gil L’Italien is an experienced epidemiologist with an extensive track record as a field researcher, an industry executive and manager of people, and as an academic leader. Gil has held roles of increasing responsibility previously within Bristol Myers Squibb Company, currently at Biogen Inc, and Yale University School of Medicine as Adjunct Assistant Professor and as Affiliated Faculty Member of the Robert Woods Johnson Clinical Scholars Program at Yale. Prior to his current professional roles, Gil was Director of Vascular Research at Massachusetts General Hospital and held a faculty appointment at Harvard Medical School. Gil has further participated in advisory committees for several government institutions such as the Agency for Health Care Research and Quality (AHRQ), US Department of Health and Human Services, The CDC Foundation Viral Hepatitis Action Coalition (VHAC), the Multiple Sclerosis Outcome Assessments Consortium (MSOAC), the Alzheimer’s Disease Technical Working Group, Green Park Collaborative, and the Merit Review Committee for the Patient Centered Outcomes Research Institute (PCORI). Most significantly, Gil is a committed philanthropist and volunteer, who has dedicated his time, talent and resources to the service of the elderly and impoverished children and families in both the US and developing countries in Africa, India, Latin & Central America. Of note, Gil recently designed and led a 3 year public health intervention that effectively treated 3,000 indigenous adults and children in rural Mexico to ameliorate the burden of soil transmitted helminthes (STH). The intervention included treatment (albendazole), hygiene (toilets, handwashing stations, latrines) and education. An overall 40% reduction in STH infection rates was observed. Gil is a member of the Board of Directors of SimplySmiles (www.simplysmiles.org) which sponsored the effort. (see my blog: http://www.simplysmiles.org/blog/2014/11/11/de-worming-update). Gil was also recently appointed to the Board of Directors for Plan USA/International. Gil has travelled extensively to Latin and Central America and is well versed as to the global health challenges faced by developing countries, and is particularly sensitive to the needs of impoverished children globally. Since 2010, Gil has been an enthusiastic supporter of Plan International’s Because I Am A Girl Program.
Gil earned his PhD in Epidemiology/Biostatistics from the Boston University School of Public Health. As evidenced by the successful de-worming study which he led in Mexico, Gil is strongly committed to the application of scientific and social studies research to quantitatively demonstrate the effectiveness of interventions, whether in global health (eg deworming) or socioeconomic (eg microfinance) areas. Such tangible evidence provides sound metrics which can positively influence both individual and group contributors, and funding agencies. Gil has three grown sons (Eric, Michael, and Paul), a daughter-in-law (Courtney) and a grandson (Rhys) who all reside in the New England area. Gil lives in Deep River, CT with his wife, Dale. When not travelling, working or volunteering, Gil enjoys mountain hiking, cycling, and babysitting for his grandson!
Dr. Aita has more than 30 years of
experience in the clinical laboratory industry working for independent,
academic and hospital labs. She has been actively involved in all aspects
of the laboratory industry and has extensive experience in the areas of
laboratory management (Clinical and Anatomic Pathology), process improvement, cost
containment, compliance and quality management.
Peter is co-founder and managing partner of InPress Media Group and the executive editor of ADC Review/Journal of Antibody-drug Conjugates. With a Ph.D. in medical sciences and various postdoctoral training/certificates, he has more than 20 years’ experience in strategic medical and scientific communication and (continued) education program development. Peter is also a seasoned journalist and writer involved in the co-production of various medical and health-related radio and television programs.
Peter is a member of a number of advisory boards for scientific/medical meetings (in oncology/hematology, protein engineering and development as well as precision, targeted and personalized medicine), including the PM Connective (http://www.pmconnective.org).
Peter was, as chairperson of EAMEI | European Association of Medical Education & Information (2004 – 2006), responsible for the educational strategic broadcast (publishing) planning and development for this non-profit organization where he helped facilitate a global cancer dialogue by using all available communications technology to reach every person touched by cancer.
At InPress Media Group, Peter is—in addition to being the executive editor of ADC Review/Journal of Antibody-drug Conjugates—also responsible for international strategic publication/education planning. He focuses on full-service medical education and communication in the consultative, promotional and non-CME realms.
PATTERSON, Ph.D. joined Gilead early in 2015 as Vice President, Biomarker
Sciences responsible for biomarker discovery and development across all
therapeutic areas (aside from direct acting antivirals) and in vitro diagnostic
programs. From 1993-2000 and 2003-2015 he was at Amgen,
Inc. initially leading their proteomics and apoptosis efforts and from 2003, as
Executive Director, Medial Sciences, establishing and leading their biomarker
and in vitro diagnostics programs across all therapeutic areas. In the interim period
(2000-2003) he was Vice President, Proteomics at Celera Genomics Group and
Chief Scientific Officer at Farmal Biomedicines, LLC. Dr. Patterson received
his B.Sc and Ph.D. in Physiology and Pharmacology at The University of
Queensland in Brisbane, Australia. He was on faculty at Cold Spring Harbor
Laboratory, New York. He has authored over 105 publications, 25 book chapters
and 9 patents.
Bruce Quinn, M.D., Ph.D., is a national leader on Medicare policy, the impact of health reform on innovation and the crafting of successful business strategies within the U.S. health care reimbursement system. He is a member of FaegreBD Consulting’s health and biosciences team and leads the reimbursement consulting practice. But with a unique set of skills, Dr. Quinn also provides significant synergies with the firm’s health care, intellectual property, life sciences and government advocacy groups.
With a nationwide client base, Dr. Quinn has worked successfully with both large and small companies in overcoming hurdles to commercialization through negotiation, understanding insightful ways to use the existing system to advantage and the mechanisms of policy change. Since 2008, he has been a full-time business strategist working with attorney and policy teams for both health care and life sciences clients.
Dr. Quinn travels nationwide to speak on health reform issues and publishes actively, most recently writing several peer-reviewed policy articles on advanced diagnostics and a series of authoritative white papers on the 2012-2014 coding reform process for genomic tests. He also writes a widely read blog, Discoveries in Health Policy, which updates readers on federal policy changes in precision medicine as well as other health topics.
Before joining FaegreBD Consulting, Dr. Quinn was a senior health policy advisor with Foley Hoag after serving as the regional Medicare medical director for the California Part B program, where he had authority for final coverage decisions on approximately 15 percent of the U.S. Medicare program. Earlier in his career, Dr. Quinn was a physician executive in the health and life sciences division of Accenture, working with the pharma, biotech and genomics industries.
Dr. Quinn is a board-certified pathologist. As a physician-scientist on the faculty of Northwestern University School of Medicine, he led pathology research for Northwestern’s NIH-funded Alzheimer Research Center. Dr. Quinn has also held academic positions at New York University School of Medicine and the UCLA Center for Health Sciences — and is the author or co-author on 30 scientific publications.
• Stanford University — Guest Instructor (for courses on health policy and medical technology innovation
• University of California San Francisco — Guest Instructor (for courses on health policy and medical technology innovation)
• Harvard Medical School — Guest Lecturer (Genomics, Value, Reimbursement course)
• International Society for Pharmacoeconomics and Outcomes Research
• Association for Molecular Pathology
• Journal of Diabetes Science and Technology — Editorial Board, 2013-Present
As head of Sanofi’s Partners and Patient Health (PiPH) team, Francis leads Sanofi efforts to engage and support advocacy groups in the U.S. to work together in new ways to improve health and healthcare. The PiPH team supports the efforts of advocacy groups to:
1. engage people in their health,
2. improve patient and patient group engagement and involvement in the innovation process,
3. identify and respond to changes in policy and the healthcare environment that impact the ability of patients to get the treatment and care they need.
The PIPH team strives to support the advocacy community and help patients by identifying alignment of stakeholder interests to drive collaborations that improve health. By convening, listening and acting as a catalyst for action, the PIPH team creates sustainable partnerships and initiatives to improve both patient health and the environment for innovation.
Prior to joining Sanofi, Francis worked as a lobbyist, advocate, entrepreneur, and non-profit executive to develop and grow many kinds of organizations, including a children’s education organization in Nicaragua, a green energy risk management start-up, and in the federal government affairs office of the Upjohn Company, among others.
Francis graduated from Georgetown University with a B.A. in Theology, and with an M.B.A from the Stanford Graduate School of Business. He currently lives in Kensington, MD with his wife Paige and their four children.
For further information, please contact
Jeffrey R. Waldron
PM Connective Inc.
To ensure our insights are robust and scalable across diseases and healthcare systems we have selected two distinct disease areas, Malignant Melanoma and Early Onset Asthma, as the test beds within which we will pursue this goal, taking the US and Europe as our regional geographic focus.
Malignant melanoma is the most serious type of skin cancer worldwide. This cancer develops in the cells, called melanocytes that produce melanin, which appears as pigmentation on the skin. Melanin is a protein defending the skin to the UV radiation. The annual incidence of malignant melanoma has intensely increased over the past few decades, with an average of 132,000 new cases of melanoma diagnosed worldwide every year.
Early onset asthma, also known as childhood-onset asthma – as the most common chronic disease among children – is when asthma symptoms begin in childhood (before 12-15). This form of asthma is usually due to genetic reasons. In fact, two risk factors to early onset asthma is the parental history of asthma, and the diagnosis of eczema, which is an inflammation of the skin, characterised by itching and redness. Asthma-related deaths among children is quite rare, nevertheless it stays an under-diagnosed and under-treated disease worldwide.
PM Connective is structured as a 501(c)(6) non-profit organization. Its operations are funded through collaborative research projects with governmental organizations, foundations and industry, through subscriptions to its publications as well as charitable contributions.
The Society for Melanoma Research 2016 Congress is a global congress that unites melanoma clinicians and researchers to focus on multidisciplinary management of melanoma/skin cancer. It provides key insight into the practical advantages of multidisciplinary are of patients with cutaneous malignancies. This is the leading meeting for cutting edge data in melanoma with over 1,000 healthcare professionals in attendance including researchers, medical oncologists, dermatologists and surgical oncologists.CLICK HERE TO LEARN MORE
Convening leaders with the experience, creativity, and motivation needed to transform the medical research system Partnering for Cures connects hundreds of decision-makers from across diseases who are motivated by the same mission – to reduce the time and
cost of getting new therapies from discovery to patients.
The Personalized Medicine Conference is an annual two-day event co-hosted and presented by Partners HealthCare Personalized Medicine, Harvard Business School, and Harvard Medical School in association with the American Association for Cancer Research; American Medical Association; American Society for Human Genetics and Personalized Medicine Coalition.
Widely considered the most prestigious event in the field, this conference attracts hundreds of national and international thought
leaders across multiple disciplines as speakers, panelists, and attendees
July 2016 - Medicine’s next step
December 2015 - Two global healthcare not-for-profit firms . . . the European Personalised Medicine Association and the PM Connective . . . announced an alliance to jointly remove barriers limiting the promise of Personalized Medicine
August 2015 - The Need to Eliminate Barriers to Personalized Medicine